UPC Invalidates Enanta's '265 Patent; Paxlovid Infringement Action Unfounded
ENTA is trading near its 52-week low of $10.22 (9.1% above the low).
Summary
The EU Unified Patent Court invalidated Enanta's '265 Patent and dismissed its infringement action against Pfizer over Paxlovid, eliminating a potential royalty/damages claim in 18 EU states.
Key Events · Legal and Risk Events · ENTA
-
UPC Rules '265 Patent Invalid
On October 29, 2026, the Unified Patent Court concluded that European Patent No. EP 4 051 265 is invalid, following a September 29, 2026 hearing on Enanta's infringement action and Pfizer's counterclaim for revocation.
-
Paxlovid Infringement Action Dismissed
In light of the validity ruling, the UPC determined that Enanta's infringement action against Pfizer and subsidiaries — covering manufacture, use and sale of Paxlovid in the 18 UPC member states — was unfounded.
-
Royalty Upside Removed
The decision eliminates the potential European royalty or damages claim tied to Paxlovid; no monetary award or license revenue results from this action.
-
Cash Position Context
As previously reported, Enanta posted a Q3 net loss of $19.5M with $211.5M in cash and a $75M at-the-market facility established July 2026 — the loss of patent leverage tightens funding options.
Analysis · ENTA · Life Sciences
The Unified Patent Court has ruled Enanta's '265 Patent invalid and, on that basis, found its infringement action unfounded, ending the European patent fight with Pfizer over Paxlovid badly for Enanta. That removes the royalty/damages upside the market may have been assigning to a Paxlovid royalty stream in the 18 participating EU states. The setback comes as the company is already burning cash — a $19.5M quarterly net loss and $211.5M in cash as previously reported — and leaning on a $75M at-the-market facility established in July 2026. Because the patent was one asserted claim, not the whole pipeline, the RSV and immunology programs are unaffected; but any valuation built on Paxlovid royalties now has to be written down.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENTA was trading at $11.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $324.7M. The 52-week trading range was $10.22 to $17.15. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.